Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …

Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

Cancer cells can evade natural killer (NK) cell activity, thereby limiting anti-tumor immunity.
To reveal genetic determinants of susceptibility to NK cell activity, we examined interacting …

The sialic acid–binding immunoglobulin-like lectin (Siglec)–sialic acid immune axis is an
evolutionarily conserved immunoregulatory pathway that provides a mechanism for …

Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …

Advances in immunotherapy have revolutionized cancer treatment, yet many patients do not
show clinical responses. While most immunotherapies target T cells, myeloid cells are the …

Phagocytes remove dead and dying cells by engaging" eat-me" ligands such as
phosphatidylserine (PtdSer) on the surface of apoptotic targets. However, PtdSer is …

Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms
which promote tumor growth and progression. Specifically, the interactions of sialic acids …

Simple Summary Sialylation is the synthetic process of sialoglycans, which are important in
tumor transformation, proliferation, metastasis, and immune evasion. The primary subjects of …

Siglec-7 (sialic acid–binding immunoglobulin-like lectin 7) is a glycan-binding immune
receptor that is emerging as a significant target of interest for cancer immunotherapy. The …